ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 225

U.S. Trends in Hospitalization Rates and Causes and in-Hospital Mortality in Rheumatoid Arthritis Patients, 2000-2014

Namrata Singh1, Yubo Gao2, Elizabeth Field3, Petar Lenert4, Jeffrey R. Curtis5 and Mary Vaughan-Sarrazin2, 1Internal Medicine, Iowa City VA Medical Center and University of Iowa, Iowa City, IA, 2University of Iowa Hospitals and Clinics, Iowa City, IA, 3Iowa City VA, Iowa City, IA, 4333 MRC Dept of Internal Med, University of Iowa, Iowa City, IA, 5University of Alabama at Birmingham, Birmingham, AL

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: morbidity and mortality and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Epidemiology and Public Health Poster I: Rheumatoid Arthritis

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Over the past two decades, major advances have been made in the treatment of RA, allowing disease remission to become an achievable goal. Although studies have looked at the trends in hospitalization for RA, contemporary data on the principal diagnoses that lead to hospitalizations and in-hospital mortality in RA are lacking. The objective of this study was to evaluate national trends in hospitalizations, underlying causes, and in-hospital mortality in RA over the past 15 years.

Methods: We used the National Inpatient Sample (NIS) from 2000-2014 to study the temporal trends in RA hospitalizations in the US. All hospitalized adults with RA (ICD9-CM 714.0 and 714.2) were included. We examined trends over time using linear regression in SAS version 9.3.

Results: Between 2000 and 2014, there were 183,983 hospitalizations with a principal discharge diagnosis of RA. The annual rates of hospitalization for principal diagnosis of RA decreased from 76.5 admissions per 1 million adults in 2000 to 30 in 2014 (P<0.0001 for trend), an admission rate reduction of 61%. Although overall annual hospitalization rates declined in the US as well in this time frame- from 14.5% to 12% (rate reduction of 16%)- the decline was not as significant as in RA. In-hospital mortality declined from 0.70% of all hospitalizations in 2000 to 0.41% in 2014 (P<0.0001 for trend). The mean (±SD) age of hospitalized RA patients remained largely stable, 62.7 (±30.7) in 2000 and 61.9 (±32.3) years in 2014. When RA was listed as a non-primary diagnosis, the most frequent principal diagnoses for admission remained diseases of the circulatory system over the entire study period. However, the rates of hospitalization for RA patients for circulatory or respiratory system diseases significantly declined between 2000 and 2014, whereas hospitalization for infectious disease causes significantly increased (Figure 1). The most common principal diagnosis leading to in-hospital mortality changed from diseases of the respiratory system in 2000 to infectious and parasitic diseases in 2014 (Figure 2).

Conclusion: Both hospitalization rates and in-hospital mortality rates in U.S. patients with RA have declined significantly over the past 15 years. Diseases of the circulatory system continue to be the principal diagnosis associated with hospitalizations whereas infectious diseases account for the hospitalizations resulting in highest in-hospital mortality in RA in recent years.


Disclosure: N. Singh, None; Y. Gao, None; E. Field, None; P. Lenert, None; J. R. Curtis, Amgen Inc., 2, 5,AbbVie Inc., 2, 5,BMS, 2, 5,Corrona, LLC, 2, 5,Janssen, 2, 5,Eli Lilly, 2, 5,Myriad, 2, 5,Pfizer, Inc., 2, 5,Roche/Genentech, 2, 5,Radius, 2, 5,UCB, Inc., 2, 5; M. Vaughan-Sarrazin, None.

To cite this abstract in AMA style:

Singh N, Gao Y, Field E, Lenert P, Curtis JR, Vaughan-Sarrazin M. U.S. Trends in Hospitalization Rates and Causes and in-Hospital Mortality in Rheumatoid Arthritis Patients, 2000-2014 [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/u-s-trends-in-hospitalization-rates-and-causes-and-in-hospital-mortality-in-rheumatoid-arthritis-patients-2000-2014/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/u-s-trends-in-hospitalization-rates-and-causes-and-in-hospital-mortality-in-rheumatoid-arthritis-patients-2000-2014/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology